Gemcitabine

Catalog No.S1714 Synonyms: LY-188011, NSC 613327

Gemcitabine  Chemical Structure

Molecular Weight(MW): 263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Mice were administered either vehicle, gemcitabine (120 mg/kg [PaCa2]) or 20 mg/kg of BBI608 i.p. After killing, tumors were collected after 7 or 14 d of treatment, for Paca-2 and FaDu cells, respectively. Single-cell suspensions were obtained after animal killing and sterile removal of tumors. Live cells were then counted and used to measure their ability to form spheres when cultured in cancer stem cell media.

    Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck.

    RNA incorporating drugs induce SG assembly. HeLa cells were treated with the RNA incorporating agents 5-azacytidine (50 uM) and 6-thioguanine (10 uM), or the DNA incorporating agents trifluorothymidine (10 uM) and gemcitabine (100 nM) for 72 h. Subsequently, the cellular localization of the SG marker protein TIAR (green) and the P-body marker protein DCP1 (red) was analyzed. Nuclei were stained with Hoechst. Scale bars represent 20 um.

    Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck.

  • Immunofluorescent analysis of gemcitabine-induced γH2A.X and 53-BP1 focus formation. a, b Immunofluorescence staining of γH2A.X(green), 53-BP1 (red), and nuclei staining with DAPI (blue) in T24 (a) and T24r GEMCI20 (b) cells after the indicated treatments. Scale bar = 50 μm

    J Exp Clin Cancer Res, 2017, 36(1):1. Gemcitabine purchased from Selleck.

    Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.

    Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 M2HVdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\POZRvUUN3ME2wMlAxODR3ODDuUS=> MXfTRW5ITVJ?
ES4 M4DiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwMECwOlU{KG6P M1fyR3NCVkeHUh?=
ACHN MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[1bFdDUUN3ME2wMlAxODh6NzDuUS=> NEHiflZUSU6JRWK=
KYSE-510 NVS2cYluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwMECwPVc2KG6P M3KxeHNCVkeHUh?=
EW-7 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\MTVlKSzVyPUCuNFAzPThibl2= MonMV2FPT0WU
BFTC-905 NGnXOpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn4Z4JiUUN3ME2wMlAxPTF3IH7N Mny4V2FPT0WU
KE-37 MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWf0[HU6UUN3ME2wMlAxPTZzIH7N MYPTRW5ITVJ?
SBC-5 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwMEC1O{BvVQ>? MXzTRW5ITVJ?
NKM-1 MlHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfpN|dKSzVyPUCuNFA4ODlibl2= MofpV2FPT0WU
RH-1 MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC3TWM2OD1yLkCwO|E5KG6P MXjTRW5ITVJ?
ALL-PO NGLwcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfQTWM2OD1yLkCwPFMhdk1? MW\TRW5ITVJ?
QIMR-WIL M1joRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXmfmU3UUN3ME2wMlAxQDl2IH7N NXPadXJZW0GQR1XS
A375 MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzoTWM2OD1yLkCwPVk2KG6P NVG0ZlZXW0GQR1XS
SIG-M5 MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n2PGlEPTB;MD6wNVA1KG6P MmnkV2FPT0WU
KGN MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrKTWM2OD1yLkCxNFghdk1? NX24Z5dlW0GQR1XS
EW-13 MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fYc2lEPTB;MD6wNVEzKG6P M1n2T3NCVkeHUh?=
NCI-SNU-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojZTWM2OD1yLkCxOkBvVQ>? MoPXV2FPT0WU
PSN1 NEfxRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDXTWM2OD1yLkCxOlUhdk1? MX7TRW5ITVJ?
HUTU-80 M4GydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUe0PZAxUUN3ME2wMlAyPjZibl2= NWjEUm9VW0GQR1XS
EW-16 NUK2TYx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzBRnFKSzVyPUCuNFI{KG6P M{H5PXNCVkeHUh?=
786-0 NUfaV2ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMEKzJI5O NGX3WmdUSU6JRWK=
ES1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\5d2lEPTB;MD6wNlY5KG6P NXH5SIJyW0GQR1XS
RKO NFP2dnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMEK3PUBvVQ>? NW\YcJhsW0GQR1XS
ESS-1 M2rkZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljITWM2OD1yLkCyPFYhdk1? M1LBfHNCVkeHUh?=
SK-UT-1 NVThe3JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmC3TWM2OD1yLkCyPVchdk1? M{ewPXNCVkeHUh?=
LB2241-RCC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHribVVKSzVyPUCuNFMyQCCwTR?= M3vobnNCVkeHUh?=
CHL-1 NYTIVHlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHYSGNKSzVyPUCuNFMzPCCwTR?= NYry[ok4W0GQR1XS
SW1783 NUf2[Vd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYS0PI5bUUN3ME2wMlA{OzZibl2= MnnmV2FPT0WU
MEL-JUSO MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nRPWlEPTB;MD6wN|kyKG6P NFjzPVVUSU6JRWK=
HT-29 NEjTR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnq3TWM2OD1yLkC0NVMhdk1? NELR[GhUSU6JRWK=
SNG-M NWjocFZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MluyTWM2OD1yLkC0NlUhdk1? MlTlV2FPT0WU
TE-15 MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFruWZFKSzVyPUCuNFQ3PCCwTR?= M1jl[3NCVkeHUh?=
HOS NGW3fWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPJbVNKSzVyPUCuNFQ5KG6P MWDTRW5ITVJ?
BB65-RCC NUG2[YNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGL5NFdKSzVyPUCuNFUyOiCwTR?= NHfubmtUSU6JRWK=
HCE-4 NWO3UXZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\pRmhKSzVyPUCuNFUzQCCwTR?= NVXhWFBvW0GQR1XS
MHH-ES-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwMEWzNUBvVQ>? M3zYZnNCVkeHUh?=
RPMI-7951 NEXhbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvxeY9KSzVyPUCuNFU1OSCwTR?= MkPPV2FPT0WU
IST-SL2 NYr6[3l7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPVTWM2OD1yLkC1PFQhdk1? MUXTRW5ITVJ?
CMK M2XaSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;lV2lEPTB;MD6wOVg3KG6P MkTzV2FPT0WU
GR-ST Mn3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwMEW5OUBvVQ>? Mo\YV2FPT0WU
NALM-6 M2XDWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{P4NGlEPTB;MD6wOlIzKG6P MmSxV2FPT0WU
RPMI-6666 M4XR[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TEfmlEPTB;MD6wOlUzKG6P M3vvXXNCVkeHUh?=
LC-2-ad MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwME[1N{BvVQ>? M2PUb3NCVkeHUh?=
ARH-77 NGrtem1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnu5TWM2OD1yLkC3NVEhdk1? MlnKV2FPT0WU
IST-MEL1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7sTJBKSzVyPUCuNFczPiCwTR?= NUPaW5g5W0GQR1XS
SW1710 NVrNdHNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH3dnUxUUN3ME2wMlA4PTFibl2= NFzCNo1USU6JRWK=
DEL MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMEi4O{BvVQ>? NV3Kd2k5W0GQR1XS
AGS MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHjOnRKSzVyPUCuNFkxOiCwTR?= MX3TRW5ITVJ?
NCI-H2122 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTPTWM2OD1yLkC5OFYhdk1? NYf0N4E5W0GQR1XS
HSC-4 NIDCNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;wO5NzUUN3ME2wMlExOiCwTR?= NUD3S|JwW0GQR1XS
AM-38 NX\jZWNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1flOGlEPTB;MD6xNlEhdk1? NYLNNmM5W0GQR1XS
769-P M2i0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLoW2JKSzVyPUCuNVI{KG6P MXvTRW5ITVJ?
RT-112 MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwMUK3JI5O MWfTRW5ITVJ?
MCF7 NH;VXHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMUO2JI5O M3LkV3NCVkeHUh?=
IGROV-1 M1nDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwMUS1JI5O MYHTRW5ITVJ?
OCI-AML2 MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u2Z2lEPTB;MD6xOFchdk1? NHe4d|FUSU6JRWK=
NCI-H1299 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3P1b2lEPTB;MD6xOVchdk1? NHPyRldUSU6JRWK=
A431 M3vRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMUizJI5O MlPLV2FPT0WU
SW982 NXz2fopPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXhb4pKSzVyPUCuNlE{KG6P NYO1W|JvW0GQR1XS
BB30-HNC NIXSTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XHeWlEPTB;MD6yN|Ehdk1? NX;oVJVHW0GQR1XS
ACN MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfIPJhkUUN3ME2wMlI1PCCwTR?= NF7EUIVUSU6JRWK=
647-V NYDWb41KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTsTWM2OD1yLkK0PEBvVQ>? NIXzZVVUSU6JRWK=
SK-PN-DW NHLqUVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknWTWM2OD1yLkK2OkBvVQ>? MmTCV2FPT0WU
LCLC-97TM1 NYTYfFFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\1OmlEPTB;MD6yOlchdk1? MoO2V2FPT0WU
LB1047-RCC M374Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vneGlEPTB;MD6yOlkhdk1? NWfJOmRnW0GQR1XS
A2780 MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwMkegcm0> MWjTRW5ITVJ?
C-33-A MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1SxTmlEPTB;MD6yO|Mhdk1? MXrTRW5ITVJ?
NCI-H2228 NELrS3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzic2pKSzVyPUCuN|E1KG6P Mn\4V2FPT0WU
TE-5 NFOye3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXETWM2OD1yLkOxOkBvVQ>? MluxV2FPT0WU
HC-1 NXHaV5o6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEK2dGJKSzVyPUCuN|I4KG6P NEXmbIRUSU6JRWK=
SK-MES-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Hkc2lEPTB;MD6zNlghdk1? NGrKfnFUSU6JRWK=
NCI-H1355 M4Dxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTW[GNiUUN3ME2wMlM5OSCwTR?= NHrEb2NUSU6JRWK=
YKG-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLUTW9KSzVyPUCuOFE6KG6P NFn4UlVUSU6JRWK=
RS4-11 NEDkfnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwNEOzJI5O MlzWV2FPT0WU
Daoy MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHaUJhKSzVyPUCuOFU3KG6P MV3TRW5ITVJ?
A3-KAW Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PFfWlEPTB;MD61OVEhdk1? NVfGW|NCW0GQR1XS
SK-MEL-30 NIHsbW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrxfHg2UUN3ME2wMlU2PCCwTR?= MoLQV2FPT0WU
U031 NVfpVZFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwNU[1JI5O NFvX[m9USU6JRWK=
SK-LMS-1 M1vlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLL[XBKSzVyPUCuOVc5KG6P MnLXV2FPT0WU
ES6 M3TwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\vPWhKSzVyPUCuOVg3KG6P M3fBZXNCVkeHUh?=
EoL-1-cell NYHEeYZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwNkG2JI5O NGrudJpUSU6JRWK=
NCI-H2009 NXX3NmNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnk[phKSzVyPUCuOlE6KG6P NEjZNpRUSU6JRWK=
A4-Fuk M1fHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\hRolOUUN3ME2wMlYzPiCwTR?= NFrhfnZUSU6JRWK=
KYSE-270 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm2TWM2OD1yLk[zOEBvVQ>? Ml;sV2FPT0WU
SK-LU-1 NW\ET3BET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwNkW1JI5O MWfTRW5ITVJ?
SW872 NYTYco5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TYOWlEPTB;MD63OlUhdk1? MoDCV2FPT0WU
ES8 NYOzc|Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUOxXHRYUUN3ME2wMlc5KG6P M4DuUnNCVkeHUh?=
G-402 M2\wO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXUdnRKSzVyPUCuO|g1KG6P M{DVSHNCVkeHUh?=
ATN-1 M1ntWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PvVmlEPTB;MD64NFchdk1? M3;aRnNCVkeHUh?=
DoTc2-4510 M1uzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGmyOFdKSzVyPUCuPVAyKG6P MYXTRW5ITVJ?
MES-SA NXTmV4ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\xfmlEPTB;MD65NFUhdk1? NFrnWHRUSU6JRWK=
SF268 NVf0cm5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rpWGlEPTB;MD65Nlchdk1? Mn[5V2FPT0WU
SF539 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrKTWM2OD1zLkCyJI5O MXLTRW5ITVJ?
NB69 MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LvOmlEPTB;MT6wOUBvVQ>? NYnZXXZLW0GQR1XS
8505C NXXqfopOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFwME[gcm0> NVi5dI91W0GQR1XS
CAL-12T M3LMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTFwMEigcm0> MoTkV2FPT0WU
BHY M3;we2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTmTWM2OD1zLkG0JI5O MlLmV2FPT0WU
LB647-SCLC M2DSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLFTWM2OD1zLkG4JI5O MXXTRW5ITVJ?
CAL-62 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3npTWlEPTB;MT6yNkBvVQ>? MVrTRW5ITVJ?
MEG-01 Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnL5TWM2OD1zLkK3JI5O NGPROGJUSU6JRWK=
MG-63 MmjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XFNmlEPTB;MT6zN{BvVQ>? MWnTRW5ITVJ?
SW620 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;3TWM2OD1zLkO1JI5O Ml3zV2FPT0WU
A388 NF75OXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G3RmlEPTB;MT6zOkBvVQ>? M4PDVHNCVkeHUh?=
BCPAP NY\GPZVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2H5OWlEPTB;MT60OUBvVQ>? M17rWnNCVkeHUh?=
P30-OHK MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\hNJZKSzVyPUGuOFYhdk1? NEfVdoNUSU6JRWK=
Ca9-22 MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDWTWM2OD1zLkW0JI5O MX\TRW5ITVJ?
VMRC-RCZ NYT4eFNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETBUVhKSzVyPUGuOVQhdk1? MX3TRW5ITVJ?
LOXIMVI MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TqdmlEPTB;MT62JI5O MYPTRW5ITVJ?
L-540 NUTsdHR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fLVmlEPTB;MT62JI5O MWDTRW5ITVJ?
NTERA-S-cl-D1 NIL3elZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPKb21KSzVyPUGuOlQhdk1? M3HzS3NCVkeHUh?=
MFH-ino M372N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoGyTWM2OD1zLk[2JI5O M{DyRnNCVkeHUh?=
Calu-6 NF\rZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnNTWhqUUN3ME2xMlc{KG6P NVrIWWxJW0GQR1XS
HEL NI\DRY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PEcGlEPTB;MT63PUBvVQ>? MlvuV2FPT0WU
CAL-33 NIrSXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TOUGlEPTB;MT64PUBvVQ>? NXz3SlRTW0GQR1XS
HSC-3 M1rSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTFwOUGgcm0> M1TvbnNCVkeHUh?=
KU812 NUXrV4NqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFwOUGgcm0> M2jYdXNCVkeHUh?=
EB2 NH7tS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nPfWlEPTB;Mj6wNUBvVQ>? MV7TRW5ITVJ?
SR NXLub|hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HHUGlEPTB;Mj6xNkBvVQ>? NGLSNoVUSU6JRWK=
NCI-H2087 M2SyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJwMUSgcm0> NIXSeW9USU6JRWK=
H4 M2HKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPpS|dVUUN3ME2yMlE5KG6P MnTFV2FPT0WU
EW-1 NIHPVlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTJwMkKgcm0> MV;TRW5ITVJ?
MC-IXC NETHZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLoe3Q2UUN3ME2yMlI3KG6P M1rCZnNCVkeHUh?=
NCI-H727 NFexbW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofITWM2OD1{LkWxJI5O M{m4XHNCVkeHUh?=
MRK-nu-1 NWji[HAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDVVldKSzVyPUKuOVchdk1? NIXnfGFUSU6JRWK=
COLO-668 M3\m[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzMTWM2OD1{Lk[2JI5O Mm\IV2FPT0WU
CGTH-W-1 NYfmPIY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTJwN{Kgcm0> NITwcIxUSU6JRWK=
CHP-212 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJwN{Wgcm0> NH\SfJpUSU6JRWK=
GI-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m0Z2lEPTB;Mj63OkBvVQ>? M{Sy[3NCVkeHUh?=
HCC1806 M3\yOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnRTWM2OD1{LkmxJI5O MlO0V2FPT0WU
HLE MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGO4OIxKSzVyPUOgcm0> NGLMdWZUSU6JRWK=
HSC-2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3P5fGlEPTB;Mz6wN{BvVQ>? NXrWS|BTW0GQR1XS
DMS-273 M1e1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTNwMEegcm0> NWPlUmFTW0GQR1XS
DU-4475 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{faVGlEPTB;Mz6xOEBvVQ>? NFzweHdUSU6JRWK=
LXF-289 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPaPWZKSzVyPUOuN|Ehdk1? M122OHNCVkeHUh?=
PANC-03-27 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K2[WlEPTB;Mz61NUBvVQ>? NHTZUGNUSU6JRWK=
GAMG NXL1VYRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPEb45KSzVyPUOuO|Qhdk1? MWDTRW5ITVJ?
NCI-H522 NX36ZZR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LXS2lEPTB;ND6zOEBvVQ>? M4WwU3NCVkeHUh?=
SW626 NIXQWJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjMSopKSzVyPUSuOFYhdk1? Ml;rV2FPT0WU
HT-144 NYPIPFhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPXTWM2OD12LkmyJI5O MmntV2FPT0WU
MEL-HO MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTVwMU[gcm0> Mkf1V2FPT0WU
BE-13 NF:zXotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTVwMkGgcm0> MUPTRW5ITVJ?
VA-ES-BJ MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\6OmlEPTB;NT6yOkBvVQ>? MWLTRW5ITVJ?
NCI-H441 NUm4S|c3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zncGlEPTB;NT62JI5O MkC2V2FPT0WU
KP-4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\ZT2lEPTB;NT62NUBvVQ>? MoL5V2FPT0WU
LoVo NGDTbo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfFXoVKSzVyPUWuO|Ehdk1? Mn\HV2FPT0WU
HT-1080 NUXEZWJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTVwOEOgcm0> M4rWUHNCVkeHUh?=
GB-1 NXe2b3BTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\xemdKSzVyPUWuPFQhdk1? MoT0V2FPT0WU
IA-LM MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq0e2pKSzVyPUWuPVEhdk1? NHz2OYZUSU6JRWK=
8-MG-BA MonCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPJRoJKSzVyPUWuPVMhdk1? MV\TRW5ITVJ?
SK-HEP-1 MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXid25KSzVyPU[uNVQhdk1? NGnnZ2tUSU6JRWK=
697 M3rKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDuV|FPUUN3ME22MlI2KG6P MkPyV2FPT0WU
KYSE-450 MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTLTWM2OD14LkOyJI5O NVPnUY94W0GQR1XS
HCC2998 MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\iWFBZUUN3ME22MlM1KG6P MVLTRW5ITVJ?
HD-MY-Z M1jIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofhTWM2OD14Lk[4JI5O NYW4ZVh6W0GQR1XS
OS-RC-2 NV\WeFNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvVTWM2OD14Lk[4JI5O NVLHTotwW0GQR1XS
SF126 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\u[mlEPTB;Nz6wOUBvVQ>? NULCOIZVW0GQR1XS
Ca-Ski MnrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\jbWlEPTB;Nz6wPUBvVQ>? MV3TRW5ITVJ?
NCI-H358 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnpUVBxUUN3ME23MlE3KG6P NETONHlUSU6JRWK=
J82 NEewd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTdwNEGgcm0> MUHTRW5ITVJ?
NCI-H2342 M3XyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTdwNkOgcm0> Mnv4V2FPT0WU
OVCAR-8 M1HTdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL0[JRKSzVyPUeuPUBvVQ>? NYDLcJZWW0GQR1XS
TE-8 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:ybWlEPTB;ODDuUS=> NYnjWGhVW0GQR1XS
ETK-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzXTWM2OD16LkC4JI5O MlroV2FPT0WU
HAL-01 NVTFVpF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\iTWM2OD16LkKgcm0> Ml:4V2FPT0WU
KYSE-150 NHLj[|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYi2TVF2UUN3ME24MlQ4KG6P NYXZR296W0GQR1XS
NCI-H810 NIX0ZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfje2lVUUN3ME24MlU3KG6P Mn:2V2FPT0WU
ONS-76 MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkCyTWM2OD16Lk[4JI5O M2q5TXNCVkeHUh?=
NMC-G1 NIHQXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRThwN{[gcm0> MV\TRW5ITVJ?
C3A MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoWzTWM2OD16Lki0JI5O MkHEV2FPT0WU
PA-1 NUezbHBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRThwOUmgcm0> NYnn[3ZPW0GQR1XS
SH-4 NXe1OXp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTlwMEKgcm0> M2HHSnNCVkeHUh?=
EFO-27 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTlwMEWgcm0> NX\MfWhSW0GQR1XS
CAPAN-1 MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfCTWM2OD17LkKzJI5O NFfFNHNUSU6JRWK=
DU-145 Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NESzbHdKSzVyPUmuNlkhdk1? M1SyT3NCVkeHUh?=
A101D NH[2dnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\3TWlEPTB;OT6zO{BvVQ>? Mk\GV2FPT0WU
ST486 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnjXnlJUUN3ME25MlQyKG6P MVjTRW5ITVJ?
NCI-H1437 NVPUc3JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojETWM2OD17LkSyJI5O NIGwfodUSU6JRWK=
HGC-27 NFfPO2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTlwNjDuUS=> MlLoV2FPT0WU
8305C MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP4TnZKSzVyPUmuOlQhdk1? MmC4V2FPT0WU
OCUB-M M{S4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\IN2lEPTB;MUCuNFMhdk1? M3jwUHNCVkeHUh?=
COLO-679 M1;wXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXflcHdTUUN3ME2xNE4xPyCwTR?= MmTJV2FPT0WU
Detroit562 NUWxOVF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\BNmlEPTB;MUCuOFIhdk1? NEf4UIlUSU6JRWK=
A204 M1PTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{O2[mlEPTB;MUGuNVYhdk1? M4SzdHNCVkeHUh?=
NCI-H1734 M{H3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDLTWM2OD1zMT6yPUBvVQ>? M{[2TnNCVkeHUh?=
MC-CAR NETydYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zUWmlEPTB;MUGuOVghdk1? M3PRbXNCVkeHUh?=
NCI-H2170 M3jEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfpPVhKSzVyPUGxMlk4KG6P NGO3fIxUSU6JRWK=
NCI-SNU-5 NWKzZ|BlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjVcGRsUUN3ME2xNk4yOyCwTR?= M1\tU3NCVkeHUh?=
HCE-T Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXlOHJKSzVyPUGyMlQzKG6P NEHydIlUSU6JRWK=
KYSE-180 NEnUZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TjU2lEPTB;MUKuPFEhdk1? M{izXXNCVkeHUh?=
C8166 NHjRdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XqfWlEPTB;MUOuNFghdk1? MkD2V2FPT0WU
NCI-H460 NVTNd3doT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLrV3VKSzVyPUGzMlU1KG6P MUTTRW5ITVJ?
SNU-449 MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fid2lEPTB;MUOuO|chdk1? NXfBd2hwW0GQR1XS
MDA-MB-468 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnvb|ZKSzVyPUG0MlEzKG6P M2fibHNCVkeHUh?=
COR-L23 NUj3Z4RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf1TWM2OD1zND6xN{BvVQ>? NVPZNIt{W0GQR1XS
CTV-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUW3bnFlUUN3ME2xOE4yPCCwTR?= M1fofnNCVkeHUh?=
BL-41 NVvFd2lRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHO1dGRKSzVyPUG0MlM4KG6P MlvSV2FPT0WU
IGR-1 NETLXG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjOTWM2OD1zND60NkBvVQ>? M{nwfHNCVkeHUh?=
TK10 NXe5WmsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvEcmd4UUN3ME2xOE41QSCwTR?= MVrTRW5ITVJ?
REH M1\ocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PH[GlEPTB;MUSuOVEhdk1? MWDTRW5ITVJ?
LU-139 MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF2LkW5JI5O M135bnNCVkeHUh?=
KP-N-YS MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGP4bmNKSzVyPUG0Mlk4KG6P M3L6dHNCVkeHUh?=
PANC-10-05 NXy3U2NxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn2[4lKSzVyPUG1MlM5KG6P NGXYRmlUSU6JRWK=
HL-60 MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fVSmlEPTB;MUWuOlkhdk1? NILseotUSU6JRWK=
T84 NXXteWo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDtTZdKSzVyPUG1Mlk3KG6P M{f0fnNCVkeHUh?=
RPMI-8226 MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfqTWM2OD1zNj6wNkBvVQ>? NVn3PYZOW0GQR1XS
UM-UC-3 M3XNZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEGzfFdKSzVyPUG2MlE3KG6P NWe1XIp2W0GQR1XS
TE-10 NXrs[lFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVe4[mVtUUN3ME2xOk4zOSCwTR?= MofMV2FPT0WU
CAL-148 NGnzeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFizSpJKSzVyPUG3MlI{KG6P NXjlV3ZuW0GQR1XS
BV-173 NWDNS3UxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTleotKSzVyPUG3MlI4KG6P NF[wU3VUSU6JRWK=
Calu-3 NGTobmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTl[IVmUUN3ME2xO{4zQSCwTR?= M3LaNHNCVkeHUh?=
RPMI-2650 NYLnNnhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTF5LkW5JI5O NV3zbo9jW0GQR1XS
MKN45 NGDqZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:1dlZKSzVyPUG3Mlc{KG6P MXfTRW5ITVJ?
NUGC-3 NEDyPZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPYbIVlUUN3ME2xPE4{PCCwTR?= NI\iXVNUSU6JRWK=
NCI-H520 NV3IOm1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrLfJFKSzVyPUG4Mlc4KG6P MVLTRW5ITVJ?
CCRF-CEM Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEiyOIdKSzVyPUG4Mlg2KG6P MWXTRW5ITVJ?
NCI-H2405 NI\Nco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfRUXNmUUN3ME2xPU4yKG6P MV7TRW5ITVJ?
ES7 M1;0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjmS4RKSzVyPUG5Mlc3KG6P M33uZnNCVkeHUh?=
BPH-1 M4nQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJyLkK4JI5O MoWwV2FPT0WU
SAS NV;CbWd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPNTWM2OD1{MD61JI5O M4\NO3NCVkeHUh?=
HuCCT1 M2rWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkS5TWM2OD1{MD61PEBvVQ>? MWjTRW5ITVJ?
LOUCY NUTyT3hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HHWWlEPTB;MkCuOlYhdk1? M3m0V3NCVkeHUh?=
NCI-H292 NEizbVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTJyLke5JI5O M2HKZXNCVkeHUh?=
G-361 NWjPe4lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG2cYsyUUN3ME2yNU4xPyCwTR?= NETCN|lUSU6JRWK=
M059J Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWraeWlWUUN3ME2yNU4xQCCwTR?= MY\TRW5ITVJ?
NCI-H1651 NVLje45kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf4TWM2OD1{MT6xNUBvVQ>? MYjTRW5ITVJ?
KALS-1 NFzaUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFO4NJlKSzVyPUKxMlM6KG6P NU\sXFhsW0GQR1XS
DJM-1 M37jOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIWybnlKSzVyPUKxMlU6KG6P NF3XUWdUSU6JRWK=
AU565 NVLCXJVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTJzLkizJI5O NIXTdnhUSU6JRWK=
HCC38 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7aTWM2OD1{MT65OUBvVQ>? MX\TRW5ITVJ?
U251 NWKycmhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT1RZpKSzVyPUKyMlI4KG6P MmXKV2FPT0WU
ABC-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJ{Lk[1JI5O M2rjXnNCVkeHUh?=
SK-NEP-1 Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTGOZZoUUN3ME2yNk46OyCwTR?= NYX5S3lUW0GQR1XS
CESS MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrISHNwUUN3ME2yN{4yQSCwTR?= NX74dYg3W0GQR1XS
MIA-PaCa-2 M132[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1X4[2lEPTB;MkOuN|Yhdk1? MX\TRW5ITVJ?
SUP-T1 NEXORlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvqTWM2OD1{Mz60O{BvVQ>? M4H2SHNCVkeHUh?=
L-428 NFTvOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzRTWM2OD1{Mz62NkBvVQ>? MnrDV2FPT0WU
SW954 NGnCdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;JboFWUUN3ME2yN{43QCCwTR?= NF[0S3lUSU6JRWK=
HO-1-N-1 NGG0fFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH2d|VEUUN3ME2yN{44PyCwTR?= Mn;JV2FPT0WU
CHP-126 NUnhSlU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3VSZdKSzVyPUK0MlE1KG6P M1L0WHNCVkeHUh?=
HMV-II MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDxd2R1UUN3ME2yOE4{PCCwTR?= MWPTRW5ITVJ?
NB10 M1zpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TCfmlEPTB;MkSuN|chdk1? M1fmcXNCVkeHUh?=
A172 M3XxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TY[2lEPTB;MkSuO|Ehdk1? MVHTRW5ITVJ?
MONO-MAC-6 M1XLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe1VYVKSzVyPUK0Mlg1KG6P NF7TU3lUSU6JRWK=
NCI-H1650 M2HKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\zc2lEPTB;MkWuOEBvVQ>? NX7FPWpxW0GQR1XS
NH-12 M4nnWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDwTWM2OD1{NT61JI5O NUnQeYlQW0GQR1XS
ML-2 MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmCwTWM2OD1{NT63OEBvVQ>? M3j6UHNCVkeHUh?=
MZ2-MEL NH;MTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJ4LkKyJI5O M{fKZ3NCVkeHUh?=
COLO-684 NWDMbXYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvQOHRKSzVyPUK2MlQyKG6P NXP4OFN1W0GQR1XS
HuP-T4 NGjpS|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJ5LkOgcm0> NFXLT3RUSU6JRWK=
SW837 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJ5Lk[yJI5O M4m4XXNCVkeHUh?=
MDA-MB-231 M2fMemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrifnZKSzVyPUK3Mlc5KG6P M2DpT3NCVkeHUh?=
KYSE-140 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfFfWo6UUN3ME2yO{46OSCwTR?= M37a[XNCVkeHUh?=
NOMO-1 NGe0V3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHrWXhOUUN3ME2yPE43QCCwTR?= MULTRW5ITVJ?
GP5d NEjtdmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJ6LkeyJI5O M3nTSHNCVkeHUh?=
COR-L105 M3nac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGq3RY5KSzVyPUK5MlQzKG6P MUXTRW5ITVJ?
LS-411N M4XrVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJ7Lki4JI5O NWXWblh4W0GQR1XS
NY M2\vRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfmTWM2OD1|MD6xPEBvVQ>? NFLXeWdUSU6JRWK=
NCI-H2030 NE\UOFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnt[HlKSzVyPUOwMlQ2KG6P MkDVV2FPT0WU
CCF-STTG1 NU\NVJV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HTeWlEPTB;M{GuOFIhdk1? NUPLSWxSW0GQR1XS
NCI-H1703 MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTNzLke4JI5O Mk\pV2FPT0WU
TUR NWTvfIRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTzTWM2OD1|Mj6wN{BvVQ>? NVzOZWdCW0GQR1XS
NOS-1 NHvWV4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjMUIdOUUN3ME2zNk41PCCwTR?= NGfmSGdUSU6JRWK=
A2058 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEe5V3NKSzVyPUOyMlg{KG6P MUfTRW5ITVJ?
LCLC-103H M3XqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTN|LkK1JI5O NXG5N21XW0GQR1XS
NCI-H510A MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf3R3dOUUN3ME2zN{4zPyCwTR?= NWnOPJdUW0GQR1XS
BC-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjwb3I5UUN3ME2zN{44PyCwTR?= M4DWUHNCVkeHUh?=
SK-CO-1 M3S4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nh[WlEPTB;M{SuNFEhdk1? MX;TRW5ITVJ?
A673 NFPFfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD2Wm1UUUN3ME2zOE4yPyCwTR?= MXPTRW5ITVJ?
VM-CUB-1 M{T0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETwWWxKSzVyPUO0MlY6KG6P NYj3N|dzW0GQR1XS
HH Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G0W2lEPTB;M{WuNFYhdk1? NFi5O2JUSU6JRWK=
CAL-27 NFn1UFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7hR3hKSzVyPUO1MlE3KG6P NXfFOHB[W0GQR1XS
NEC8 NU\L[3dLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHNXWZ3UUN3ME2zOU4{PyCwTR?= MXTTRW5ITVJ?
BxPC-3 MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLlTWM2OD1|Nj65NUBvVQ>? Mn\UV2FPT0WU
SNB75 M4r0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HMSmlEPTB;M{euNlQhdk1? NX7rWGhxW0GQR1XS
NB13 NFXZdFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTN6LkKzJI5O NFX5d4pUSU6JRWK=
SK-OV-3 NGTNTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zye2lEPTB;M{iuO|Qhdk1? NWrHdXV[W0GQR1XS
ME-180 NXe4OZFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHrTWM2OD1|OD64JI5O NH34TpNUSU6JRWK=
JiyoyeP-2003 NEmzOpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTGb3ltUUN3ME2zPU4{QCCwTR?= MWrTRW5ITVJ?
LU-134-A MknTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLJTWM2OD12MD6wNkBvVQ>? NYftflZwW0GQR1XS
LS-123 NYTCUHFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoW1TWM2OD12MD6yPEBvVQ>? M4i3VXNCVkeHUh?=
COLO-800 NFLLSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTRyLkW2JI5O M1HrNHNCVkeHUh?=
LB831-BLC M2\a[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3JTWM2OD12MT64OUBvVQ>? NXfYWphMW0GQR1XS
NCI-H747 NX3sUo9mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TjSGlEPTB;NEKuNlghdk1? Mk\BV2FPT0WU
MZ7-mel NETtSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTR{Lk[2JI5O MmfhV2FPT0WU
GT3TKB MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrib3BKSzVyPUSyMlczKG6P MWfTRW5ITVJ?
MOLT-16 M1PqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkSxTWM2OD12Mz6wOUBvVQ>? M4jZSXNCVkeHUh?=
23132-87 NHLBbWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHH6eHpKSzVyPUSzMlA2KG6P M{D5e3NCVkeHUh?=
PF-382 M2LuTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnn4TWM2OD12ND6yNkBvVQ>? NHfkbJVUSU6JRWK=
ES3 M2Xjcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHyTWM2OD12ND62JI5O MXnTRW5ITVJ?
SW756 NYrKfoJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf3TWM2OD12NT6xOEBvVQ>? M4TlOXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

Protocol

Solubility (25°C)

In vitro DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
water (warmed)
For best results, use promptly after mixing.
52mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage powder
Synonyms LY-188011, NSC 613327

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT01535924 Recruiting Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma Kristie Blum|Ohio State University Comprehensive Cancer Center February 9, 2012 Phase 1|Phase 2
NCT01285037 Recruiting Cancer Eli Lilly and Company September 9, 2009 Phase 1
NCT01828736 Completed Recurrent Bladder Cancer|Stage IV Bladder Cancer|Transitional Cell Carcinoma of the Bladder Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie|Roche Pharma AG February 9, 2004 Phase 2
NCT01352962 Active, not recruiting Urethral Neoplasms|Neoplasms, Urethral|Ureter Cancer|Cancer of the Urethra|Urethral Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5, 2011 Phase 1
NCT03027284 Recruiting Advanced Cancer|Metastatic Cancer|Biliary Tract Carcinoma|Cholangiocarcinoma|Gall Bladder Carcinoma|Solid Tumor|Non-Hodgkins Lymphoma Eli Lilly and Company February 3, 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • Answer:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID